Effect of Treatment with Direct Acting Antiviral on Glycemic Control in Patients with Diabetes Mellitus and Chronic Hepatitis C

ABSTRACT Introduction and aim. The effect of the new direct acting antiviral drugs (DAAs) for chronic hepatitis C (HCV) on glycemic control is unknown. Materials and methods. We conducted a retrospective cohort study of patients who were treated for chronic HCV with direct-acting antiviral medications at a single academic institution between May 2013 and April 2016. Univariate analysis was performed comparing subjects pre- and post-treatment. Results. One hundred seventy-five consecutive adult patients were treated for chronic HCV and met enrollment criteria. The majority (80.8%) were genotype 1 and overall cohort sustained virologic response at week 12 (SVR12) was 97.8%. Thirty-one (18.5%) had diabetes mellitus (DM); twenty-six had pre- and post-treatment HbA1c values. Of these, 76.9% were male and 61.5% had cirrhosis. Ninety-six percent were prescribed sofosbuvir-based therapy and all but one (96.8%) achieved SVR12. Three patients were started on treatment despite meeting the definition for poorly controlled DM (HbA1c > 9 mg/dL). There was no significant difference when comparing pre-treatment (7.36 mg/dL, 95% CI 6.55-8.16) to post-treatment HbA1c (7.11 mg/dL, 95% CI 6.34-7.88, p = 0.268). Thirty-one percent of subjects required dose escalation or the initiation of insulin based therapy during treatment. Discussion. Although chronic HCV is associated with exacerbation of insulin resistance, our results showed HbA1c to be unaffected by eradication of chronic HCV with DAA in diabetic patients with and without cirrhosis. Paradoxically, almost 1/3 of patients required escalation of anti-diabetic therapy during treatment. Long-term studies are warranted to understand the relationship between HCV viral eradication and insulin metabolism.

Saved in:
Bibliographic Details
Main Authors: Stine,Jonathan G., Wynter,Javelle A., Niccum,Blake, Kelly,Virginia, Caldwell,Stephen H., Shah,Neeral L.
Format: Digital revista
Language:English
Published: Asociación Mexicana de Hepatología A.C. 2017
Online Access:http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1665-26812017000200215
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1665-26812017000200215
record_format ojs
spelling oai:scielo:S1665-268120170002002152017-09-11Effect of Treatment with Direct Acting Antiviral on Glycemic Control in Patients with Diabetes Mellitus and Chronic Hepatitis CStine,Jonathan G.Wynter,Javelle A.Niccum,BlakeKelly,VirginiaCaldwell,Stephen H.Shah,Neeral L. Hepatology Cirrhosis Liver Portal hypertension Viremia ABSTRACT Introduction and aim. The effect of the new direct acting antiviral drugs (DAAs) for chronic hepatitis C (HCV) on glycemic control is unknown. Materials and methods. We conducted a retrospective cohort study of patients who were treated for chronic HCV with direct-acting antiviral medications at a single academic institution between May 2013 and April 2016. Univariate analysis was performed comparing subjects pre- and post-treatment. Results. One hundred seventy-five consecutive adult patients were treated for chronic HCV and met enrollment criteria. The majority (80.8%) were genotype 1 and overall cohort sustained virologic response at week 12 (SVR12) was 97.8%. Thirty-one (18.5%) had diabetes mellitus (DM); twenty-six had pre- and post-treatment HbA1c values. Of these, 76.9% were male and 61.5% had cirrhosis. Ninety-six percent were prescribed sofosbuvir-based therapy and all but one (96.8%) achieved SVR12. Three patients were started on treatment despite meeting the definition for poorly controlled DM (HbA1c > 9 mg/dL). There was no significant difference when comparing pre-treatment (7.36 mg/dL, 95% CI 6.55-8.16) to post-treatment HbA1c (7.11 mg/dL, 95% CI 6.34-7.88, p = 0.268). Thirty-one percent of subjects required dose escalation or the initiation of insulin based therapy during treatment. Discussion. Although chronic HCV is associated with exacerbation of insulin resistance, our results showed HbA1c to be unaffected by eradication of chronic HCV with DAA in diabetic patients with and without cirrhosis. Paradoxically, almost 1/3 of patients required escalation of anti-diabetic therapy during treatment. Long-term studies are warranted to understand the relationship between HCV viral eradication and insulin metabolism.info:eu-repo/semantics/openAccessAsociación Mexicana de Hepatología A.C.Annals of Hepatology v.16 n.2 20172017-04-01info:eu-repo/semantics/articletext/htmlhttp://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1665-26812017000200215en10.5604/16652681.1231579
institution SCIELO
collection OJS
country México
countrycode MX
component Revista
access En linea
databasecode rev-scielo-mx
tag revista
region America del Norte
libraryname SciELO
language English
format Digital
author Stine,Jonathan G.
Wynter,Javelle A.
Niccum,Blake
Kelly,Virginia
Caldwell,Stephen H.
Shah,Neeral L.
spellingShingle Stine,Jonathan G.
Wynter,Javelle A.
Niccum,Blake
Kelly,Virginia
Caldwell,Stephen H.
Shah,Neeral L.
Effect of Treatment with Direct Acting Antiviral on Glycemic Control in Patients with Diabetes Mellitus and Chronic Hepatitis C
author_facet Stine,Jonathan G.
Wynter,Javelle A.
Niccum,Blake
Kelly,Virginia
Caldwell,Stephen H.
Shah,Neeral L.
author_sort Stine,Jonathan G.
title Effect of Treatment with Direct Acting Antiviral on Glycemic Control in Patients with Diabetes Mellitus and Chronic Hepatitis C
title_short Effect of Treatment with Direct Acting Antiviral on Glycemic Control in Patients with Diabetes Mellitus and Chronic Hepatitis C
title_full Effect of Treatment with Direct Acting Antiviral on Glycemic Control in Patients with Diabetes Mellitus and Chronic Hepatitis C
title_fullStr Effect of Treatment with Direct Acting Antiviral on Glycemic Control in Patients with Diabetes Mellitus and Chronic Hepatitis C
title_full_unstemmed Effect of Treatment with Direct Acting Antiviral on Glycemic Control in Patients with Diabetes Mellitus and Chronic Hepatitis C
title_sort effect of treatment with direct acting antiviral on glycemic control in patients with diabetes mellitus and chronic hepatitis c
description ABSTRACT Introduction and aim. The effect of the new direct acting antiviral drugs (DAAs) for chronic hepatitis C (HCV) on glycemic control is unknown. Materials and methods. We conducted a retrospective cohort study of patients who were treated for chronic HCV with direct-acting antiviral medications at a single academic institution between May 2013 and April 2016. Univariate analysis was performed comparing subjects pre- and post-treatment. Results. One hundred seventy-five consecutive adult patients were treated for chronic HCV and met enrollment criteria. The majority (80.8%) were genotype 1 and overall cohort sustained virologic response at week 12 (SVR12) was 97.8%. Thirty-one (18.5%) had diabetes mellitus (DM); twenty-six had pre- and post-treatment HbA1c values. Of these, 76.9% were male and 61.5% had cirrhosis. Ninety-six percent were prescribed sofosbuvir-based therapy and all but one (96.8%) achieved SVR12. Three patients were started on treatment despite meeting the definition for poorly controlled DM (HbA1c > 9 mg/dL). There was no significant difference when comparing pre-treatment (7.36 mg/dL, 95% CI 6.55-8.16) to post-treatment HbA1c (7.11 mg/dL, 95% CI 6.34-7.88, p = 0.268). Thirty-one percent of subjects required dose escalation or the initiation of insulin based therapy during treatment. Discussion. Although chronic HCV is associated with exacerbation of insulin resistance, our results showed HbA1c to be unaffected by eradication of chronic HCV with DAA in diabetic patients with and without cirrhosis. Paradoxically, almost 1/3 of patients required escalation of anti-diabetic therapy during treatment. Long-term studies are warranted to understand the relationship between HCV viral eradication and insulin metabolism.
publisher Asociación Mexicana de Hepatología A.C.
publishDate 2017
url http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1665-26812017000200215
work_keys_str_mv AT stinejonathang effectoftreatmentwithdirectactingantiviralonglycemiccontrolinpatientswithdiabetesmellitusandchronichepatitisc
AT wynterjavellea effectoftreatmentwithdirectactingantiviralonglycemiccontrolinpatientswithdiabetesmellitusandchronichepatitisc
AT niccumblake effectoftreatmentwithdirectactingantiviralonglycemiccontrolinpatientswithdiabetesmellitusandchronichepatitisc
AT kellyvirginia effectoftreatmentwithdirectactingantiviralonglycemiccontrolinpatientswithdiabetesmellitusandchronichepatitisc
AT caldwellstephenh effectoftreatmentwithdirectactingantiviralonglycemiccontrolinpatientswithdiabetesmellitusandchronichepatitisc
AT shahneerall effectoftreatmentwithdirectactingantiviralonglycemiccontrolinpatientswithdiabetesmellitusandchronichepatitisc
_version_ 1756227381299773440